PMID- 27307508
OWN - NLM
STAT- MEDLINE
DCOM- 20171227
LR  - 20220318
IS  - 1537-6591 (Electronic)
IS  - 1058-4838 (Print)
IS  - 1058-4838 (Linking)
VI  - 63
IP  - 6
DP  - 2016 Sep 15
TI  - Human Immunodeficiency Virus and Risk of Type 2 Diabetes in a Large Adult Cohort 
      in Jos, Nigeria.
PG  - 830-5
LID - 10.1093/cid/ciw381 [doi]
AB  - BACKGROUND: Human immunodeficiency virus (HIV) infection and the use of 
      antiretroviral therapy (ART) may increase the risk of type 2 diabetes mellitus 
      (T2DM). However, data from regions with a high burden of HIV/AIDS are limited. We 
      determined the prevalence of T2DM at the time of presentation to a large HIV 
      clinic in Nigeria, as well as the incidence of diabetes 12 months following ART 
      initiation. METHODS: Data from patients enrolled for ART from 2011 to 2013 was 
      analyzed, including 2632 patients on enrollment and 2452 reevaluated after 12 
      months of ART commencement. The presence of diabetes, and demographic, clinical, 
      and biochemical data were retrieved from standardized databases. CD4(+), HIV RNA 
      load, and hepatitis C virus status were noted. Bivariate and logistic regressions 
      were used to identify risk factors for T2DM. RESULTS: Baseline T2DM prevalence 
      was 2.3% (95% confidence interval, 1.8%-2.9%); age, but not body mass index 
      (BMI), was a risk factor for diabetes. After 12 months of ART, an additional 5.3% 
      had developed T2DM. Newly developed diabetes was not associated with age, but was 
      associated with BMI. There were no significant associations between prevalent or 
      incident diabetes and CD4(+), viral load, or type of ART. CONCLUSIONS: Diabetes 
      is not uncommon in HIV-infected individuals at the time of presentation to HIV 
      services. Patients initiating ART have a high risk of developing diabetes in the 
      first year of ART. Excessive weight gain should be avoided, as incident diabetes 
      was associated with a BMI >/=25.0 kg/m(2).
CI  - (c) The Author 2016. Published by Oxford University Press for the Infectious 
      Diseases Society of America.
FAU - Isa, Samson E
AU  - Isa SE
AD  - Department of Medicine, University of Jos and Jos University Teaching Hospital 
      Prevention Initiative of Nigeria Clinic, Jos University Teaching Hospital.
FAU - Oche, Agbaji O
AU  - Oche AO
AD  - Department of Medicine, University of Jos and Jos University Teaching Hospital 
      Prevention Initiative of Nigeria Clinic, Jos University Teaching Hospital.
FAU - Kang'ombe, Arthur R
AU  - Kang'ombe AR
AD  - Department of Clinical Sciences, Liverpool School of Tropical Medicine, United 
      Kingdom.
FAU - Okopi, Joseph A
AU  - Okopi JA
AD  - Prevention Initiative of Nigeria Clinic, Jos University Teaching Hospital 
      Department of Microbiology, University of Jos.
FAU - Idoko, John A
AU  - Idoko JA
AD  - Department of Medicine, University of Jos and Jos University Teaching Hospital 
      National Agency for the Control of AIDS, Abuja, Nigeria.
FAU - Cuevas, Luis E
AU  - Cuevas LE
AD  - Department of Clinical Sciences, Liverpool School of Tropical Medicine, United 
      Kingdom.
FAU - Gill, Geoffrey V
AU  - Gill GV
AD  - Department of Clinical Sciences, Liverpool School of Tropical Medicine, United 
      Kingdom.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160615
PL  - United States
TA  - Clin Infect Dis
JT  - Clinical infectious diseases : an official publication of the Infectious Diseases 
      Society of America
JID - 9203213
RN  - 0 (Anti-HIV Agents)
SB  - IM
MH  - Adult
MH  - Anti-HIV Agents/therapeutic use
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/*complications/*epidemiology
MH  - Female
MH  - HIV Infections/*complications/drug therapy/*epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nigeria/epidemiology
MH  - Risk Factors
PMC - PMC4996137
OTO - NOTNLM
OT  - HIV/AIDS
OT  - Nigeria
OT  - antiretroviral therapy
OT  - antiretrovirals
OT  - diabetes
EDAT- 2016/06/17 06:00
MHDA- 2017/12/28 06:00
PMCR- 2016/06/15
CRDT- 2016/06/17 06:00
PHST- 2016/03/02 00:00 [received]
PHST- 2016/05/26 00:00 [accepted]
PHST- 2016/06/17 06:00 [entrez]
PHST- 2016/06/17 06:00 [pubmed]
PHST- 2017/12/28 06:00 [medline]
PHST- 2016/06/15 00:00 [pmc-release]
AID - ciw381 [pii]
AID - 10.1093/cid/ciw381 [doi]
PST - ppublish
SO  - Clin Infect Dis. 2016 Sep 15;63(6):830-5. doi: 10.1093/cid/ciw381. Epub 2016 Jun 
      15.